Doxorubicin chemotherapy in advanced transitional cell carcinoma

Area of Science:

• Oncology
• Pharmacology

Background:

• Transitional cell carcinoma is a significant cause of cancer-related mortality.
• Advanced urothelial tumors present treatment challenges.

Purpose of the Study:

• To evaluate the efficacy and safety of doxorubicin hydrochloride in patients with advanced transitional cell carcinoma.
• To assess the impact of doxorubicin hydrochloride on pain and quality of life.

Main Methods:

• Intravenous doxorubicin hydrochloride (Adriamycin) administered at 60-75 mg/m² every three weeks.
• 25 patients with advanced transitional cell carcinoma were enrolled.
• 19 patients were evaluable for objective response.

Main Results:

• One partial objective remission lasting five months was observed in 19 evaluable patients.
• All 7 patients with bone pain experienced symptomatic relief.
• 12 patients reported significant subjective improvement, averaging six-and-a-half months.
• Minimal side effects included alopecia, mild leukopenia, and mild stomatitis; no cardiotoxicity was noted.

Conclusions:

• Doxorubicin hydrochloride demonstrates important antitumor activity in advanced urothelial tumors.
• The agent is well-tolerated with minimal toxicity.
• Further controlled clinical trials are warranted to establish its role in monotherapy and combination regimens.